Chronic Hepatitis News

Healio Gastroenterology presents the following reports on recent news in COVID-19.

Core protein allosteric modulator RO7049389 was safe and demonstrated antiviral activity in patients with chronic hepatitis B infection, according to research published in Lancet Gastroenterology and Hepatology.

Chronic hepatitis B virus, whether current or past, was not associated with increased incidence of acute liver injury or death among patients with COVID-19, according to research presented at the International Liver Congress.

A treatment regimen of low dose VBI-2601 (BRII-179) injections in patients with chronic hepatitis B exhibited positive safety, tolerability and efficacy, according to a poster presented at the International Liver Congress.

Long-term tenofovir treatment in pediatric patients with chronic hepatitis B was well tolerated and correlated with a high rate of viral suppression, according to a study presented at the International Liver Congress.

VIR-2218, an investigational small interfering ribonucleic acid therapeutic, was well tolerated in patients for the treatment of chronic hepatitis B virus, according to research presented at the International Liver Congress.

Treatment with hepatic arterial infusion chemotherapy in combination with sintilimab allowed for surgical resection and produced survival rates similar to lesser advanced hepatocellular carcinoma, according to a presenter at The International Liver Congress.

Monotherapy with bulevirtide among patients with compensated hepatitis delta was safe and well tolerated, according to a presentation at the International Liver Congress.

Tenofovir reduced the severity of COVID-19 infection among patients with chronic hepatitis B, according to a presentation at The Digital International Liver Congress.

Under an FDA-approved expansion of the pediatric indication, children as young as age 3 years are now able to receive Epclusa for the treatment of chronic hepatitis C virus regardless of HCV genotype or severity.